🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans

Jack Allen

Stock Analyst at Robert W. Baird

(0.04)
# 4,883
Out of 5,152 analysts
337
Total ratings
28.2%
Success rate
-17.3%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Jack Allen

Voyager Therapeutics
Nov 9, 2026
Maintained: Buy
Price Target: $18 → $12
Current: $1.73
Upside: +593.64%
BioMarin Pharmaceutical
Oct 28, 2026
Maintained: Hold
Price Target: $65
Current: $55.35
Upside: +17.43%
Kardigan
Oct 21, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $13.60
Upside: +216.18%
Cellectis
Sep 15, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.05
Upside: +661.90%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $40 → $16
Current: $16.75
Upside: -4.48%
Taysha Gene Therapies
Jun 30, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $4.25
Upside: +252.94%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $19.11
Upside: +198.27%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $10.12
Upside: +384.19%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Hold
Price Target: $7 → $13
Current: $12.28
Upside: +5.86%
Allogene Therapeutics
Apr 14, 2026
Reiterated: Buy
Price Target: $7 → $9
Current: $1.23
Upside: +631.71%
Downgraded: Hold
Price Target: $180 → $7
Current: $5.84
Upside: +19.86%
Reiterated: Buy
Price Target: $8 → $1
Current: $0.2917
Upside: +242.82%
Reiterated: Buy
Price Target: $64 → $46
Current: $19.54
Upside: +135.41%
Reiterated: Hold
Price Target: $52 → $44
Current: $51.47
Upside: n/a
Reiterated: Buy
Price Target: $5
Current: $1.03
Upside: n/a
Reiterated: Buy
Price Target: $10 → $6
Current: $2.60
Upside: n/a
Reiterated: Hold
Price Target: $5 → $4
Current: $2.07
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $0.0003
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $10.63
Upside: n/a
Reiterated: Buy
Price Target: $84
Current: $31.96
Upside: n/a
Reiterated: Hold
Price Target: $27
Current: $8.71
Upside: n/a
Downgraded: Hold
Price Target: $200 → $25
Current: $13.30
Upside: n/a